Imp.
RCH in Melbourne have to be sure that ATL 1102 in treating DMD children is safe.
THese children are very sick and I'm sure Parents want to give them QUALITY OF LIFE.
We hope ANP can provide this.There has been a great deal of study with a Qualified team of Scientists who are confident that the END result will benefit these young sick children.
AS you know Sarepta have to prove up more data for efficiency and safety.Otherwise the FDA will withdraw their drug...Goolsberry the ex CEO of Sarepta is well aware of what's required.Im sure the Ethics Board will give ANP the green light shortly.
MOdifications have to be made to the Trial Design...I'm sure the FDA is aware that SPMS is the final stage of the MS Cycle and they will do everything to help ANP. A minnow in the Biotech World.
ANP Price at posting:
3.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)